BELLUS Health’s portfolio focuses on novel therapeutics for conditions with high unmet medical need.

Its pipeline of projects includes the Company’s lead drug candidate BLU-5937 for chronic cough and several other partnered clinical-stage drug development programs.

BLU-5937 is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, a clinically validated target for chronic cough. BLU-5937 has the potential to be a best-in-class therapeutic for chronic cough patients who do not respond to current therapies. The Company expects by the end of November 2018 top-line results of the clinical Phase 1 study for BLU-5937. The study was initiated in July 2018. The clinical Phase 2 study is expected to be initiated in 2019 in chronic cough patients. In preclinical studies, BLU-5937 exhibited a potent anti-tussive effect without affecting taste perception and an excellent safety profile. A commercial assessment performed by Torreya Insights on behalf of the Company concluded that, in the United States alone, more than 26 million adults have chronic cough and more than 2.6 million of these patients suffer from refractory chronic cough lasting for more than a year.

BELLUS Health also has economic interests in other partnered clinical-stage drug development programs.

 

Share this

Sign up for email alerts

Email Address *
 
Enter the code shown above.